Vaxil Bio (VXL.V) Osake Kurssi

Vaxil Bio Ltd. is an immunotherapy biotech company, which is engaged in the development of immunotherapies such as neoantigen-like peptide products, and antibodies to treat cancer and infectious diseases. The company is headquartered in Toronto, Ontario. The company went IPO on 2011-03-02. The firm is focused on a novel drug discovery and development platform based on signal peptides (SPs) to fight infectious diseases and cancer. The Company’s most advanced product, ImMucin, is a MUC1 SP-derived vaccine, which completed a Phase I/II clinical trial in multiple myeloma. The firm also has a SP-based COVID-19 vaccine candidate and a SP-based tuberculosis vaccine / treatment candidate. In addition, The Company has mAb candidates for the treatment of oncology and infectious diseases to be used alone, and in combination with other treatments. The firm has also initiated a pre-clinical program for a drug delivery polymer that targets high affinity E-selectin (P-Esbp), which the Company licensed for development and commercialization from BGN Technologies. The firm exploits the unique properties of SP domains on crucial proteins to develop targeted therapies against cancer targets and infectious disease pathogens.